Adding docetaxel to standard care improved failure-free survival and progression-free survival (PFS) but not overall survival, metastatic PFS, or prostate cancer-specific survival.
Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.
Adding olaparib to durvalumab did not improve progression-free or overall survival.
Guidelines recommend open adrenalectomy for masses larger than 6 cm due to concerns that a minimally invasive approach could lead to inferior outcomes. New findings suggest that is not the case.
SHR3680 plus ADT improved radiographic progression-free survival and overall survival, when compared with bicalutamide plus ADT.
Adults with new onset type 2 diabetes in 2 years after diagnosis had increased risk of all-cause mortality
Updated findings from the ENZAMET trial show that adding enzalutamide to testosterone suppression offers clinically meaningful improvements in overall survival.
Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and better patient-reported quality-of-life.
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
